NYMC Faculty Publications

The Efficacy of Platelet-Rich Plasma Gel in MRSA-Related Surgical Wound Infection Treatment: An Experimental Study in an Animal Model

DOI

10.1007/s00068-017-0852-0

Journal Title

European Journal of Trauma and Emergency Surgery

First Page

859

Last Page

867

Document Type

Article

Publication Date

December 2018

Department

Surgery

Abstract

INTRODUCTION: The wound healing properties of platelet-rich plasma (PRP) gel have been documented in many studies. PRP gel has also become a promising agent for treating surgical site infections. In this study, we investigated the antibacterial activity and wound healing effectiveness of PRP in an animal model of Methicillin-resistant Staphylococcus aureus subsp. aureus (MRSA N315)-contaminated superficial soft tissue wounds. MATERIALS AND METHODS: Subcutaneous wounds in Wistar Albino male rats were created by making two cm midline incisions followed by inoculation of microorganisms. Study groups comprised of Sham (no treatment), PRP alone, MRSA alone, MRSA + PRP, MRSA + Vancomycin, and MRSA + Vancomycin + PRP groups. We inoculated 0.1 mL (3 x 10(8) CFU/mL) of MRSA in contaminated groups. After 8 days, all rats were killed, wounds were excised and subjected to histopathologic examination, and MRSA counts were determined. RESULTS: MRSA counts in MRSA, MRSA + PRP, MRSA + Vancomycin and MRSA + Vancomycin + PRP groups were 5.1 x 10(6) (SD +/- 0.4) CFU/mL, 4.3 x 10(6) (SD +/- 0.7) CFU/mL, 2.3 x 10(6) (SD +/- 0.3) CFU/mL, 1.1 x 10(6) (SD +/- 0.4) CFU/mL, respectively. The inflammation scores of MRSA + PRP, MRSA + Vancomycin, and MRSA + Vancomycin + PRP groups were significantly lower than the MRSA group. MRSA + Vancomycin + PRP group inflammation score was significantly lower than the MRSA + PRP group. DISCUSSION: All treatment groups were effective in wound healing and decreasing the MRSA counts. MRSA + PRP combined created identical inflammation scores to the PRP group. More in vivo studies are required to corroborate these findings.

Share

COinS